Cargando…
HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction
Background. Protease inhibitor (PI)–based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestati...
Autores principales: | Papp, Eszter, Mohammadi, Hakimeh, Loutfy, Mona R., Yudin, Mark H., Murphy, Kellie E., Walmsley, Sharon L., Shah, Rajiv, MacGillivray, Jay, Silverman, Michael, Serghides, Lena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264589/ https://www.ncbi.nlm.nih.gov/pubmed/25030058 http://dx.doi.org/10.1093/infdis/jiu393 |
Ejemplares similares
-
Erratum to: Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial
por: Siou, Kaitlin, et al.
Publicado: (2017) -
Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial
por: Siou, Kaitlin, et al.
Publicado: (2016) -
HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation
por: Mohammadi, Hakimeh, et al.
Publicado: (2018) -
Perinatal outcomes in women living with HIV‐1 and receiving antiretroviral therapy—a systematic review and meta‐analysis
por: Shinar, Shiri, et al.
Publicado: (2021) -
Perceived acceptability of progesterone to prevent preterm births and low birth weight among HIV-infected and HIV-uninfected Zambian pregnant women
por: Wong, Jeffrey Man Hay, et al.
Publicado: (2017)